Actively Recruiting
Evaluation of NIRSense Wearable Sensor Patch for Continuous Monitoring in Cardiogenic Shock and Heart Failure Patients
Led by NIRSense Inc. · Updated on 2026-09-17
20
Participants Needed
1
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the investigational NIRSense Tissue Oximetry Sensor System, a noninvasive wearable device that uses near-infrared spectroscopy, photoplethysmography, and electrocardiographyimpedance cardiography sensors to continuously monitor tissue oxygen saturation and other vital metrics in adults with acute myocardial infarction or acute decompensated heart failure. This observational pilot study focuses on patients admitted to a cardiac intensive care unit who are in specific shock stages SCAI B, C, or D. The goal is to assess the devices feasibility and its ability to detect early signs of worsening cardiogenic shock compared to standard clinical measurements. During the study, up to 20 participants will wear sensor patches placed on the sternum, forearm, and other specified locations for about 24 to 72 hours while receiving standard cardiac intensive care. The device continuously collects various physiological data, which will be compared with standard hemodynamic and laboratory tests as well as the patients clinical progress. There is no intervention or treatment change based on the device data, and the study includes two groups those admitted for coronary angiography due to myocardial infarction and those admitted for pulmonary artery catheter insertion due to heart failure. Participants will be monitored during their standard intensive care stay, with continuous sensor data collection alongside routine clinical assessments such as vital signs, ECG, blood pressure, cardiac output measurements, and laboratory values. Researchers will analyze the correlation between sensor data and clinical parameters, device feasibility, patient tolerance, and relationships between sensor trends and shock stage changes. The study does not include follow-up visits, and participant involvement lasts for the duration of their cardiac ICU admission, approximately 24 to 72 hours.
CONDITIONS
Brief Title
Clinical Evaluation of NIRSense Tissue Oximetry Sensor Monitoring to Early Detect Cardiogenic Shock
Research Team
T
Thibault Roumengous, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here